Research Focus
The Trau Group, led by Senior Group Leader Professor Matt Trau, is dedicated to developing improved point-of-care diagnostics from the benchtop to bedside, with the goal of significantly enhancing patient outcomes and helping to transition the medical system towards early disease detection and personalised treatment. By understanding disease epigenetics and combining chemistry with nanotechnology, the Group’s research aims to provide improved accuracy over existing diagnostic devices, at a cheaper price.
Professor Trau has a joint appointment with SCMB.
Research Highlights
Videos
An End to Cancer Mortality with Nano-Diagnostics | Matt Trau | TEDxUQ
Research with the Trau Group
The New Science of Ageing & Wellness - Dr Leroy Hood, Ravinder Sajwan & Matt Trau
Personalised Treatment for Breast Cancer, presented by Professor Matt Trau
It's a Small World - documentary on Nanotechnology & it's benefits to cancer research
Professor Matt Trau, NBCF funded researcher talks about his diagnostic research
On Liberty Ep.10 Matt Trau: Lessons to prevent the next pandemic
News
-
-
Small science, giant steps: The AIBN 2022 in review
6 December 2022 -
New molecule chip changing the face of modern manufacturing
7 September 2022 -
Gold nanoparticles detect signals from cancer cells
27 February 2020 -
Federal funding supports important health research
30 August 2019 -
Golden partnership to advance UQ cancer test
30 July 2019 -
A Universal DNA Nano-Signature for Cancer
5 December 2018
